EYP Architecture & Engineering announced a new managing principal, Chris Baylow, AIA, and executive director of business development and strategy, Kelly Bliss, to lead the firm’s Boston office. In these roles, Baylow and Bliss will leverage their team of experts and sophisticated problem-solvers to increase visibility of the firm and help clients accomplish their goals.

Baylow brings 30 years of experience in client leadership, project management, planning and design to his promotion as managing principal of the Boston office. In this role, he’ll continue to be a trusted advisor for many higher education and science and technology clients throughout New England and plans to forge new relationships in the local region.

“I’m excited to grow our integrated practice of architecture, engineering, and building performance expertise here in the Boston office,” said Baylow. “I view the work we do here as a holistic journey with our clients, and I look forward to supporting our EYP team of trusted advisors who guide clients towards achieving their goals .”

As director of business development and strategy, Bliss will collaborate with firm leadership in higher education as well as science and technology to develop and execute effective strategies for promoting the Boston office. In this role, Bliss aims to expand EYP’s presence in the Northeast as the company continues to grow in the Boston market.

“EYP has been the best kept secret in the Northeast, and the firm is on an upward trajectory that I’m proud to be part of,” said Bliss. “I’m eager to share EYP’s accomplishments and increase awareness of the firm for its depth of expertise, design excellence, and dedication to problem-solving on behalf of clients.”

The Boston office is home to specialists in academic innovation and STEM, student housing and modernization projects, as well as complex research and technology. Some of the firm’s recognized clients include Northeastern University, Boston University, Dartmouth College, Harvard University, Jackson Laboratories, Regeneron Pharmaceuticals, and United Therapeutics.